Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

Research and Markets: Global Dermatology Drug Pipeline Capsule - 2012

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

Fore Pharma's latest report Global Dermatology Drug Pipeline Capsule - 2012' provides up-to-date information on key research and development activities in the global dermatology drug market. It covers active pipeline molecules under development in various stages of clinical trials, preclinical research, and drug discovery for Acne, Alopecia, Atopic Dermatitis, Malignant Melanoma, Psoriasis, and Rosacea.

This report helps executives track their competitor's pipeline molecules. The information presented in this report can be used for identifying partners, evaluating business opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

The report provides information on pipeline molecules by company, mechanism of action, stage (phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and drug discovery), and geography (North America, Europe, and Asia).

- Dermatology Drug Pipeline Insights

- Acne Drug Pipeline Insights

- Alopecia Drug Pipeline Insights

- Atopic Dermatitis Drug Pipeline Insights

- Malignant Melanoma Drug Pipeline Insights

- Psoriasis Drug Pipeline Insights

- Rosacea Drug Pipeline Insights

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.